ALLMedicine™ HER2+ Center
Research & Reviews 1,040 results
https://clinicaltrials.gov/ct2/show/NCT04379596
May 20th, 2022 - DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-positive adv...
https://www.ncbi.nlm.nih.gov/pubmed/35579591
Clinical Advances in Hematology & Oncology : H&O; Alder L, Sammons S et. al.
May 18th, 2022 - Up to half of all patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer will eventually acquire brain metastases (BrMs), which are associated with reduced overall survival and decreased quality of life. A...
https://clinicaltrials.gov/ct2/show/NCT05378464
May 18th, 2022 - Patients with HER2-positive (HER2+) metastatic breast cancer will be treated with 6 weekly injections of dendritic cell (DC1) vaccines in combination with trastuzumab and pepinemab. Investigators hypothesize these therapies will elicit CD4+ HER2 s...
https://clinicaltrials.gov/ct2/show/NCT05132582
May 17th, 2022 - Control arm: Placebo given orally twice daily plus trastuzumab and pertuzumab every 21 days Experimental arm: Tucatinib 300 mg given orally twice daily plus trastuzumab and pertuzumab every 21 days Trastuzumab and pertuzumab will be administered a...
https://doi.org/10.1080/14728222.2022.2077189
Expert Opinion on Therapeutic Targets; Menendez JA, Lupu R
May 13th, 2022 - Brain metastasis (BrM) is a key contributor to morbidity and mortality in breast cancer patients, especially among high-risk epidermal growth factor receptor 2-positive (HER2+) and triple-negative/basal-like molecular subtypes. Optimal management ...
Guidelines 1 results
https://doi.org/10.1007/s12094-012-0836-9
Clinical & Translational Oncology : Official Publication ... Rivera F, Grávalos C et. al.
Jun 23rd, 2012 - Gastric adenocarcinomas are tumours of decreasing incidence in the Western world, although they are still the fourth leading cause of cancer mortality. The purpose of these clinical guidelines is to provide recommendations for the diagnosis and tr...
Drugs 9 results see all →
Clinicaltrials.gov 100 results
https://clinicaltrials.gov/ct2/show/NCT04379596
May 20th, 2022 - DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-positive adv...
https://clinicaltrials.gov/ct2/show/NCT05378464
May 18th, 2022 - Patients with HER2-positive (HER2+) metastatic breast cancer will be treated with 6 weekly injections of dendritic cell (DC1) vaccines in combination with trastuzumab and pepinemab. Investigators hypothesize these therapies will elicit CD4+ HER2 s...
https://clinicaltrials.gov/ct2/show/NCT05132582
May 17th, 2022 - Control arm: Placebo given orally twice daily plus trastuzumab and pertuzumab every 21 days Experimental arm: Tucatinib 300 mg given orally twice daily plus trastuzumab and pertuzumab every 21 days Trastuzumab and pertuzumab will be administered a...
https://clinicaltrials.gov/ct2/show/NCT05319873
May 12th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety of the combination of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer. (Phase 1 Dose Escalation Trial) II. To determine the recommended phase 2 dose of ribociclib ...
https://clinicaltrials.gov/ct2/show/NCT03913234
May 10th, 2022 - This trial is performed in a multicenter, single-group, and phases IB and II clinical trial. This is a single-group clinical trial of the effects of ribociclib, letrozole and trastuzumab in postmenopausal women with HR+, HER2+ advanced breast canc...
News 525 results
https://www.mdedge.com/hematology-oncology/article/254265/breast-cancer/clinical-edge-journal-scan-commentary-breast-cancer
Erin Roesch, MD
Apr 29th, 2022 - Erin Roesch, MD The phase 2 DESTINY-Breast01 trial showed impressive antitumor activity with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a heavily pretreated patient population with metastatic human epidermal growth factor recept.
https://www.mdedge.com/hematology-oncology/article/254060/breast-cancer/pyrotinib-boosts-survival-lapatinib-resistant-her2
Apr 25th, 2022 - Key clinical point: Pyrotinib-based therapy could prolong survival in patients with lapatinib-resistant, human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer, including those with brain metastases and those who benefi.
https://www.mdedge.com/hematology-oncology/article/254059/breast-cancer/local-therapy-remains-standard-care-pt1an0m0-her2
Apr 25th, 2022 - Key clinical point: In patients with pT1aN0M0, human epidermal growth factor receptor 2 positive (HER2+) invasive breast cancer adding systemic therapy after surgical excision had clinical outcomes similar to local therapy alone. Major finding: Ov.
https://www.mdedge.com/hematology-oncology/article/254051/breast-cancer/trastuzumab-deruxtecan-bests-trastuzumab-emtansine
Apr 25th, 2022 - Key clinical point: Trastuzumab deruxtecan was superior to trastuzumab emtansine in reducing the risk for disease progression or death in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer who had been.
https://www.onclive.com/view/patient-profile-1-second-line-therapy-for-her2-mbc
Apr 17th, 2022 - Transcript: Neil Iyengar, MD: Let's move on and hear about what happened next. It sounds like she subsequently went on to develop brain metastases. Milana Dolezal, MD, MSci: Unfortunately, she then developed brain metastases. She did come in w...
